Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 3.150
+0.038 (1.21%)
At close: Dec 2, 2025
EGX:RMDA Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 3,948 | 2,769 | 1,922 | 1,484 | 1,246 | 960.17 | Upgrade | |
Revenue Growth (YoY) | 70.28% | 44.03% | 29.54% | 19.06% | 29.81% | 7.41% | Upgrade |
Cost of Revenue | 2,093 | 1,487 | 1,018 | 765.28 | 669.61 | 514.34 | Upgrade |
Gross Profit | 1,855 | 1,281 | 904.06 | 718.67 | 576.82 | 445.83 | Upgrade |
Selling, General & Admin | 805.4 | 558.11 | 444.06 | 360.96 | 303.18 | 258.18 | Upgrade |
Other Operating Expenses | -30.76 | -27.3 | -7.34 | -6.04 | -0.76 | -1.16 | Upgrade |
Operating Expenses | 790.16 | 558.54 | 458.3 | 376.41 | 302.53 | 258.82 | Upgrade |
Operating Income | 1,065 | 722.93 | 445.76 | 342.26 | 274.29 | 187.01 | Upgrade |
Interest Expense | -505.15 | -307.21 | -191.2 | -89.07 | -91.03 | -96.64 | Upgrade |
Interest & Investment Income | 32.6 | 65.85 | 62.9 | 56.73 | 59.97 | 64.16 | Upgrade |
Currency Exchange Gain (Loss) | -1.99 | 56.24 | 18.68 | 25.65 | -0.6 | -1.7 | Upgrade |
Other Non Operating Income (Expenses) | -16.33 | -11.7 | -8.84 | -6.99 | -8.31 | -7.58 | Upgrade |
EBT Excluding Unusual Items | 574.28 | 526.11 | 327.31 | 328.58 | 234.33 | 145.25 | Upgrade |
Gain (Loss) on Sale of Assets | 0.13 | 0.01 | 0.14 | -0.13 | -0.72 | -0.14 | Upgrade |
Pretax Income | 574.41 | 526.12 | 327.45 | 328.45 | 233.61 | 145.11 | Upgrade |
Income Tax Expense | 135.84 | 124.31 | 74.24 | 75.57 | 53.52 | 33.59 | Upgrade |
Earnings From Continuing Operations | 438.57 | 401.81 | 253.21 | 252.89 | 180.09 | 111.51 | Upgrade |
Minority Interest in Earnings | -17.43 | -14.44 | -8.35 | -7.21 | 1 | 0.67 | Upgrade |
Net Income | 421.13 | 387.37 | 244.86 | 245.68 | 181.09 | 112.18 | Upgrade |
Preferred Dividends & Other Adjustments | 23.53 | 23.53 | 21.36 | 16.76 | 14.7 | 14.7 | Upgrade |
Net Income to Common | 397.61 | 363.84 | 223.5 | 228.91 | 166.39 | 97.48 | Upgrade |
Net Income Growth | 46.52% | 58.20% | -0.33% | 35.67% | 61.43% | 36.15% | Upgrade |
Shares Outstanding (Basic) | 1,510 | 1,497 | 1,491 | 1,475 | 1,523 | 1,523 | Upgrade |
Shares Outstanding (Diluted) | 1,514 | 1,505 | 1,501 | 1,483 | 1,523 | 1,523 | Upgrade |
Shares Change (YoY) | 0.70% | 0.23% | 1.27% | -2.62% | - | - | Upgrade |
EPS (Basic) | 0.26 | 0.24 | 0.15 | 0.16 | 0.11 | 0.06 | Upgrade |
EPS (Diluted) | 0.26 | 0.24 | 0.15 | 0.15 | 0.11 | 0.06 | Upgrade |
EPS Growth | 48.41% | 62.39% | -3.56% | 41.28% | 70.69% | 18.31% | Upgrade |
Free Cash Flow | -513.12 | -371.85 | -135.54 | -5.03 | 188.68 | -249.31 | Upgrade |
Free Cash Flow Per Share | -0.34 | -0.25 | -0.09 | -0.00 | 0.12 | -0.16 | Upgrade |
Dividend Per Share | 0.053 | 0.053 | 0.067 | - | - | - | Upgrade |
Dividend Growth | -20.69% | -20.69% | - | - | - | - | Upgrade |
Gross Margin | 46.99% | 46.28% | 47.03% | 48.43% | 46.28% | 46.43% | Upgrade |
Operating Margin | 26.98% | 26.11% | 23.19% | 23.06% | 22.01% | 19.48% | Upgrade |
Profit Margin | 10.07% | 13.14% | 11.63% | 15.43% | 13.35% | 10.15% | Upgrade |
Free Cash Flow Margin | -13.00% | -13.43% | -7.05% | -0.34% | 15.14% | -25.96% | Upgrade |
EBITDA | 1,164 | 802.33 | 514.61 | 403.67 | 316.61 | 239.55 | Upgrade |
EBITDA Margin | 29.49% | 28.98% | 26.77% | 27.20% | 25.40% | 24.95% | Upgrade |
D&A For EBITDA | 99.06 | 79.4 | 68.85 | 61.41 | 42.31 | 52.54 | Upgrade |
EBIT | 1,065 | 722.93 | 445.76 | 342.26 | 274.29 | 187.01 | Upgrade |
EBIT Margin | 26.98% | 26.11% | 23.19% | 23.06% | 22.01% | 19.48% | Upgrade |
Effective Tax Rate | 23.65% | 23.63% | 22.67% | 23.01% | 22.91% | 23.15% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.